WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding of generic medicines to the branded reference medicine (in joined cases C-253/20 and C-254/20), and about which we published a blog on 24 November 2022. The second addressed the impact of anti-tampering devices on the possibility, and objective necessity, to rebox (in C-224/20 and C-147/20), and about which we published a blog on 2 December 2022.
Recommended articles
EU harmonizes THC limits in hemp seed (food) as from 1 January 2023 – Update Belgium
The EU regulator has harmonized the maximum levels for tetrahydrocannabinol (THC) in hemp seeds throughout the Union within the food contaminants framework.
Read on
The recent tax and social security reforms on copyright income: what employers need to know
Following an intense debate, the legislator introduced a new tax scheme applicable to copyright income. Main raison for this initiative is the assumed abuse of the until then beneficial tax regime. Under the amended tax rules, employees still qualify for the special tax scheme, but with a stricter legal framework.
Read on
European Parliament passes sweeping due diligence rules on deforestation-free supply chains for products such as cocoa, coffee and soy
An EU Regulation on the making available on the Union market as well as export from the Union of certain commodities and products associated with deforestation and forest degradation (“Deforestation Regulation”) was agreed upon by the EU legislators in December 2022. The European Parliament has now green-lighted the Provisional Agreement at this month’s plenary session.
Read on